ArticleOpen veterinary journal2026
Development of a suspension-based vero cell culture platform for the efficient propagation of lumpy skin disease virus.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lumpy skin disease virus (LSDV) is an increasingly prevalent pathogen of significant global concern. It is indigenous to Africa and the Middle East and has recently spread to Europe and Asia. Vaccine-based control programs represent the most effective preventive strategy for disease management. The extraordinary worldwide dissemination of the virus necessitates establishing effective, scalable vaccine production systems to meet both local and global vaccine demand. Vaccine manufacturing has depended on LSDV multiplication in adherent cell cultures, thus constraining large-scale manufacturing. Aim: This study aimed to enhance and maximize the productivity of an LSDV on a suspension-adapted cell line. VERO cells are anchorage-dependent, and there are currently no commercially available suspension VERO cell lines. The creation of our customized cells constitutes a singular R&D investment. Vero cells were adapted for suspension growth to facilitate subcultivation, enhance process scalability, and reduce production costs. Methods: A robust small-scale suspension culture system of Vero cells was developed for the efficient propagation of LSDV. A preliminary step for industrial production in bioreactors, with optimized passage time and initial cell density, along with other factors such as cell density, medium composition, and agitation rates. Results: The modified cells exhibited remarkable viability and proliferation rates in suspension, reaching 1.94 × 10 Conclusion: This study shows high-titer LSDV production in suspension-adapted Vero cell culture (up to 7 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.